Use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in context of COVID-19 outbreak: a retrospective analysis Use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in context of COVID-19 outbreak: a retrospective analysis Journal: Frontiers of Medicine
Frontiers of Medicine Frontiers of Medicine Frontiers of Medicine Authors: Jiuyang Xu, Chaolin Huang, Guohui Fan, Zhibo Liu, Lianhan Shang, Fei Zhou, Yeming Wang, Jiapei Yu, Luning Yang, Ke Xie, Zhisheng Huang, Lixue Huang, Xiaoying Gu, Hui Li, Yi Zhang, Yimin Wang, Frederick G.
Posting time: 06 Jul 2020
DOI: 10.
WeChat link: click here to read the WeChat article
Click here to read the WeChat articleClick here to read the WeChat article Introduction to Xu Jiuyang of Tsinghua University School of Medicine, Huang Chaolin of Wuhan Jinyintan Hospital, Cao Bin and Wang Chen of China-Japan Friendship Hospital, etc.
Guide Since the beginning of the epidemic, the relationship between hypertension and the new coronavirus pneumonia (COVID-19) has received widespread attention
Therefore, for COVID-19 patients with a history of hypertension, whether it is necessary to stop ACEI/ARB drugs or switch to other types of antihypertensive drugs is an urgent problem to be solved
Abstract Since the outbreak of the novel coronavirus pneumonia, the relationship between angiotensinase inhibitors (ACEI) and angiotensin II receptor antagonists (ARB) antihypertensive drugs and COVID-19 has received extensive attention
Summary The research team retrospectively analyzed the clinical information of 702 COVID-19 patients admitted to Wuhan Jinyintan Hospital from December 29, 2019 to February 15, 2020, and screened out 101 patients who had a history of hypertension and were undergoing oral blood pressure reduction The treated COVID-19 patients were retrospectively analyzed
Among 101 patients, 40 received ACEI/ARB treatment, and the treatment plan of the remaining 61 patients did not include ACEI/ARB (mainly CCB)
Comments This study is based on the data from the early stage of the epidemic, and it has not been found that long-term ACEI/ARB medication will change the clinical outcome of COVID-19 patients
Reviews Recently, a number of retrospective studies on the use of ACEI/ARB in the COVID-19 epidemic have been published both domestically and internationally
There are still more questions that we do not have clear answers: Does long-term use of ACEI/ARB drugs have a protective effect on the incidence and disease outcome of COVID-19? After the onset of COVID-19, does short-term application of ACEI/ARB drugs have a therapeutic effect? Is the impact of ACEI/ARB on COVID-19 the same in people with hypertension, people with other underlying diseases (such as diabetes, chronic heart failure, etc.
Summary
The possible effects of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs) on COVID-19 disease severity have generated considerable debate.
Original information
Textual information textual information title
title Use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in context of COVID-19 outbreak: a retrospective analysis
Use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in context of COVID-19 outbreak: a retrospective analysis Use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in context of COVID-19 outbreak: a retrospective analysis author
author Jiuyang Xu, Chaolin Huang, Guohui Fan, Zhibo Liu, Lianhan Shang, Fei Zhou, Yeming Wang, Jiapei Yu, Luning Yang, Ke Xie, Zhisheng Huang, Lixue Huang, Xiaoying Gu, Hui Li, Yi Zhang, Yimin Wang, Frederick G .
mechanism
mechanism 1.
2.
3.
Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases, China-Japan Friendship Hospital, Beijing 100029, China
4.
Institute of Respiratory Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China
5.
Institute of Clinical Medical Sciences, China-Japan Friendship Hospital, Beijing 100029, China
6.
Beijing University of Chinese Medicine, Beijing 100029, China
7.
Department of Respiratory Medicine, Capital Medical University, Beijing 100029, China
8.
Graduate School of Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100730, China
9.
Department of Medicine, University of Virginia School of Medicine, Charlottesville, VA 22904, USA
10.
Centre for Tropical Medicine and Global Health, University of Oxford, Oxford OX1 2JD, UK
11.
Tsinghua University–Peking University Joint Center for Life Sciences, Beijing 100084, China
12.
Chinese Academy of Engineering, Beijing 100088, China
Corresponding Authors Bin Cao and Chen Wang
Corresponding Authors Cite this article
Cite this article Jiuyang Xu, Chaolin Huang, Guohui Fan, Zhibo Liu, Lianhan Shang, Fei Zhou, Yeming Wang, Jiapei Yu, Luning Yang, Ke Xie, Zhisheng Huang, Lixue Huang, Xiaoying Gu, Hui Li, Yi Zhang, Yimin Wang, Frederick G .
Hayden, Peter W.
Horby, Bin Cao, Chen Wang.
Use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in context of COVID-19 outbreak: a retrospective analysis.
Front.
Med.
, 2020, 14(5): 601–612 https://doi.
org/10.
1007/s11684-020-0800-y
https://doi.
org/10.
1007/s11684-020-0800-y https://doi.
org/10.
1007/s11684-020-0800-y https://journal.
hep.
com.
cn/fmd/EN/10.
1007/s11684-020-0800-y
https://journal.
hep.
com.
cn/fmd/EN/10.
1007/s11684-020-0800-y https://journal.
hep.
com.
cn/fmd/EN/10.
1007/s11684-020-0800-y https://link.
springer.
com/article/10.
1007/s11684-020-0800-y
https://link.
springer.
com/article/10.
1007/s11684-020-0800-y https://link.
springer.
com/article/10.
1007/s11684-020-0800-y
Click the blue "Read Original" in the lower left corner to download the full text and learn more
.
Thank the author for his trust and support to Frontiers of Medicine
.
Frontiers of Medicine "Frontier" series of English academic journals
"Frontier" series of English academic journals "Frontier" series of English academic journals "Frontier" series of English academic journals The "Frontiers" series of English academic journals sponsored by the Ministry of Education and Higher Education Press was officially launched in 2006 and distributed to the world in online and print editions
.
The series of journals includes four themes of basic sciences, life sciences, engineering technology, and humanities and social sciences.
It is the most extensive English academic journal group covering disciplines in China, 13 of which are included in SCI, and others are also included in A&HCI, Ei, MEDLINE or corresponding international disciplines.
It is included in the authoritative search system and has a certain international academic influence
.
The series of journals adopt the online priority publishing method to ensure that the articles are published at the fastest speed
.
Higher Education Press was selected as a cluster project of the "Excellence Action Plan for Chinese Sci-tech Journals"
.
In the Frontier series of journals: 13 are included by SCI; 1 are included by A&HCI; 6 are included by Ei; 2 are included by MEDLINE; 11 are Chinese core journals of science and technology; 16 are included by CSCD
.
China Academic Frontier Journal Network
China Academic Frontier Journal Net China Academic Frontier Journal Net http://journal.
hep.
com.
cn
http://journal.
hep.
com.
cn http://journal.
hep.
com.
cn
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
